Patient Education
Share your love
Foundation Fighting Blindness releases 4-year RUSH2A data to public | Ophthalmology Times
(Image Credit: AdobeStock/Ar_TH) Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A, an ongoing natural history study for patients with mutations in the USH2A gene, which causes Usher syndrome type 2A or nonsyndromic retinitis pigmentosa…
Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1 | Ophthalmology Times
(Image Credit: AdobeStock/Treecha) Opus Genetics has dosed the first patient in its OPGx-BEST1 phase 1/2 clinical trial, BIRD-1, for Best disease (BEST1). Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by…
Eradicating Demodex Blepharitis and Improving MGD with Lotilaner | Ophthalmology Times
The program begins with a discussion on the everyday challenges eye care professionals face in recognizing subtle signs of eyelid disease. The speaker explains how a structured clinical workflow—combining careful slit-lamp examination, patient history, and microscopic confirmation—can help practitioners avoid…
Enova Advanced EDoF IOL with Light Tailoring Tech
The Enova Advanced® Extended Depth of Focus (EDoF) IOL, developed by VSY Biotechnology GmbH, represents a significant evolution in intraocular lens technology. Built on advanced optical innovation and material science, this lens is designed to offer natural vision, seamless focus, and…
AAO 2025: The rise of presbyopia research | Ophthalmology Times
AnnMarie Hipsley, PDT, PhD, founder of ACE Vision Group spoke to the group’s advances in ocular biomechanics and vision science. The central theme was moving beyond a lens-centric approach to vision, historically the foundation of presbyopia research, towards a systems-level…
STAAR Surgical announces amendments to Alcon merger agreement, further delays deal | Ophthalmology Times
(Image Credit: AdobeStock/Andrey Popov) The timeline for the proposed Alcon acquisition of STAAR Surgical has once again been extended as STAAR announced amendments to the Alcon merger agreement. Prior to the amendment, STAAR delayed its Special Meeting of Stockholders twice—which has…
AAO 2025: The value of RGB imaging in OCT | Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, a professor of ophthalmology at UCLA and the Doheny Eye Institute, discussed advancements in ophthalmological imaging technology, specifically focusing on the Silverstone platform with RGB imaging capabilities. The key innovation of this platform is the…
AAO 2025: Innovations in surgical visualization and imaging | Ophthalmology Times
Katherine Talcott, MD, a retina specialist at the Cleveland Clinic’s Cole Eye Institute, explores the evolving landscape of retinal surgery, focusing on emerging imaging technologies. She begins by distinguishing 2 main categories of technological advancements: intraoperative optical coherence tomography (OCT)…
FDA accepts resubmitted ONS-5010 BLA from Outlook Therapeutics | Ophthalmology Times
(Image Credit: AdobeStock) The FDA has accepted for review a biologics license application (BLA) from Outlook Therapeutics for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). ONS-5010 is a recombinant humanized monoclonal antibody (mAb) that selectively…
Apellis announces 5-year GALE study data in GA | Ophthalmology Times
Image credit: ©Proxima Studio/AdobeStock) Apellis Pharmaceuticals recently announced post hoc analysis data from the GALE extension study. The new data are the result of 5 years of continuous treatment with pegcetacoplan injection (Syfovre) in patients with geographic atrophy (GA) secondary…